Last updated: Aug 26, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT06780098 | 2 | Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I) | Unknown mechanism |
| NCT07391670 | 1 | A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab | PD-L1 -- immune checkpoint blockade (monoclonal antibody) |
| NCT07250477 | 2 | Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer | Unknown mechanism |
| NCT07100080 | 2, 3 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Trop-2 -- antibody-drug conjugate (izalontamab brengitecan) + platinum-based chemotherapy |
| NCT07388524 | 3 | Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial | PD-L1 -- immune checkpoint inhibitor (atezolizumab) + recombinant human hyaluronidase |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 33 |
| Tianjin Medical University Cancer Institute and Hospital | 29 |
| Shanghai Pulmonary Hospital, Shanghai, China | 29 |
| Hunan Province Tumor Hospital | 23 |
| Shanghai Chest Hospital | 22 |
Countries/regions with the most active trial sites for lung cancer (nsclc). A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 1, 2026 | NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | Indocyanine green -- fluorescent dye for surgical navigation |
| Nov 30, 2026 | NCT07579221 | Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer | EZH2 + PRMT5 -- epigenetic enzyme inhibitors |
| Oct 30, 2026 | NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | LRRC15 -- radiolabeled monoclonal antibody (radioimmunotherapy) |
| Sep 14, 2026 | NCT07619599 | A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab | PD-1 -- antibody (immune checkpoint inhibitor) |
| Sep 7, 2026 | NCT07436858 | Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer | HER2 -- radiolabeled antibody for PET imaging (diagnostic antibody) |
| Aug 17, 2026 | NCT07784959 | Study of NXP900 With Lorlatinib in ALK+ Lung Cancer | ALK -- tyrosine kinase inhibitor (TKI) (Lorlatinib); Unknown mechanism (NXP900) |
| Aug 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| Aug 2026 | NCT07675876 | Inhaled Cromolyn Sodium in Patients With Locally Advanced Lung Cancer | Mast cell stabilization -- inhibition of mast cell degranulation (mast cell stabilizer) |
You've seen the lung cancer (nsclc) landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.